“This positive tie-up will enable SMG to tap on CHA’s reputable obstetrics & gynaecology (O&G) specialisations; pursue overseas expansion with an established international healthcare group; and access to cash for expansion,” says Maybank analyst John Cheong in a Friday report.
SINGAPORE (Feb 20): Singapore Medical Group could see a re-rating as its market recognition and track record grows following its tie-up with Korean healthcare group CHA Medical Group, according to Maybank Kim Eng.
This comes after news that CHA Medical Group, one of Asia’s leading medical groups with operations in US and Japan, will be taking a 8.8% stake in SMG by subscribing for 30 million new shares in the company.
